BST2 ISOFORMS: DISTRIBUTION AND POTENTIAL USE IN CANCER THERAPEUTICS by Muhsin, Ahmed
The Texas Medical Center Library 
DigitalCommons@TMC 
The University of Texas MD Anderson Cancer 
Center UTHealth Graduate School of 
Biomedical Sciences Dissertations and Theses 
(Open Access) 
The University of Texas MD Anderson Cancer 
Center UTHealth Graduate School of 
Biomedical Sciences 
8-2020 
BST2 ISOFORMS: DISTRIBUTION AND POTENTIAL USE IN 
CANCER THERAPEUTICS 
Ahmed Muhsin 
Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Muhsin, Ahmed, "BST2 ISOFORMS: DISTRIBUTION AND POTENTIAL USE IN CANCER THERAPEUTICS" 
(2020). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical 
Sciences Dissertations and Theses (Open Access). 1021. 
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1021 
This Thesis (MS) is brought to you for free and open 
access by the The University of Texas MD Anderson 
Cancer Center UTHealth Graduate School of Biomedical 
Sciences at DigitalCommons@TMC. It has been 
accepted for inclusion in The University of Texas MD 
Anderson Cancer Center UTHealth Graduate School of 
Biomedical Sciences Dissertations and Theses (Open 
Access) by an authorized administrator of 
DigitalCommons@TMC. For more information, please 
contact digitalcommons@library.tmc.edu. 
BST2 ISOFORMS: DISTRIBUTION AND POTENTIAL USE IN CANCER 
THERAPEUTICS 
by 
Ahmed Mohammed Muhsin, MBChB MPH 
APPROVED: 
Laura Bover, Ph.D. 
Advisory Professor 
Stephanie Watowich, Ph.D. 
s�-----
Jagannadha Sas try, Ph.D. 
Robert Orlowski, M.D., Ph.D. 
APPROVED: 
Dean, The University of Texas 










Presented to the Faculty of  
 
The University of Texas 
MD Anderson Cancer Center UTHealth  
Graduate School of Biomedical Sciences  
 
in Partial Fulfillment 
of the Requirements 
for the Degree of 















        This research work is dedicated to my role model for professionalism, the 
person who fed me the love of science since childhood and taught me that nothing is 
impossible with research… my father Professor Mohammed Muhsin.  
        This thesis is also dedicated to the most caring, loving and amazing woman in 
my life, my mother.  
        Lastly, without her patience and unlimited support, this research would never 
happen. To my wife and soulmate, Hawraa, I hope you liked this work … and please 
buckle up, I am going to start my PhD soon... I love you!  













         There is not an enough way to express my appreciation and gratitude to my 
advisor, Professor Bover, for all her guidance, teaching and support during the past 
three years I spent at the Monoclonal Antibody Core facility. Since I first heard about 
it in 1997, I was fascinated by the hybridoma technology and eagerly wanted to 
know every aspect about it. My dream came true and I was so lucky to learn this 
technology here at MD Anderson Cancer Center, and under the supervision of Dr. 
Bover, who herself received first-hand training from the inventor of this technology 
and the Nobel Prize winner, Dr. Milstein.  
        With no other graduate students or postdocs in the core facility, the training and 
assistance I received from the lab members were crucial for my success. I deeply 
want to thank our laboratory manager, Long Vien, who taught me every step in the 
hybridoma generation, from immunization to subcloning. I also want to thank Mrs. 
Janis Johnson for assisting me in the purification process and Julio Pollarolo for 
teaching me the various methods of ELISA. Lastly, I truly appreciate the invaluable 
encouragement and support from Felipe Amaya-Manzanares and Zhuang Wu. I will 
miss you all. 
        I want to express my sincere appreciation to the members of my advisory 
committee for their guidance and time. Professors Robert Orlowski, Stephanie 
Watowich, Jagannadha Sastry and Shao-Cong Sun, thank you all so much. 
        I am truly grateful to the core facilities at MD Anderson Cancer Centers for the 




staff at the Advanced Cytometry & Sorting Facility at South Campus (ACSF), 
especially Karen Ramirez, Sarah Schneider and Veena Papanna. I would also like to 
thank the scientists at the Functional Genomic Core, Dr. Yutong Sun and Dr. Chien-
Chia Cheng, for their help and training in the BST2 Knockdown project. 
        Lastly, I am very thankful to Dr. Inés Bravo at the Laboratory of Molecular 
Pathology, Hospital El Cruce, Florencio Varela, Buenos Aires, Argentina for 
performing immunohistochemistry assays on human breast cancer tissues, using the 

















BST2 ISOFORMS: DISTRIBUTION AND POTENTIAL USE IN CANCER 
THERAPEUTICS 
Ahmed Mohammed Muhsin, MBChB MPH 
Advisory Professor: Laura Bover, Ph.D. 
 
        Identifying a cancer-specific cellular target is one of the key factors that can 
pave a “bench to the bedside” path of a target therapy. Bone marrow stromal cell 
antigen 2 (BST2) is a raft-associated type II transmembrane protein with an unusual 
topology. Analyses showed a variable degree of BST2 expression in most organs. 
Two research groups identified different BST2 isoforms of BST2 generated by 
posttranscriptional modification. In this research, I studied the long BST2 isoform’s 
distribution in breast tissue and B cell lines using the novel monoclonal antibody 
(MAb) LA5, an anti-BST2-long MAb. This approach revealed the expression of the 
long BST2 isoform in the malignant B-cell lines. Moreover, immunohistochemistry 
staining of ductal breast carcinoma tissues showed the ability of the generated MAb 
to detect long BST2-positive cancer cells surrounded by negatively stained normal 
tissue, indicating LA5 specificity for this isoform. In contrast to the existing clone 
26F8 that binds to all isoforms, the LA5 MAb specifically recognized malignant cells 
while distinguishing and excluding surrounding normal cells. The specificity of the 
generated MAb clearly demonstrates potential diagnostic value in detecting the early 




patients. The other segment of my research entailed exploring the roles of BST2 in 
breast cancer, using a loss-of-function approach with BST2-targeting short hairpin 
RNA (shRNA) in the T47D breast cancer cell line. Silencing BST2 was associated 
with a statistically significant reduction in the viability of T47D (p value < 0.05) but 
had no impact its proliferation (p value = 0.6). Lastly, the downstream effects of 
BST2 silencing was evaluated through reverse phase protein array (RPPA) and 
revealed the statistically significant upregulation of four genes: MAPK1/MAPK3, 
HES1, FN1 and STAT3 (p value < 0.05). All these genes play different roles in the 
survival mechanisms that breast cancer cells may initiate when a critical pathway 
becomes compromised. By examining the adaptive cellular responses to BST2 
silencing, this study offers insight into potential gene expression changes in breast 
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1.1 What is BST2?  
        Bone marrow stromal cell antigen 2 (BST2) is a type II transmembrane protein, 
consisting of 180 amino acids (1). This protein was first described in 1994 by Goto et 
al. as a B-cell specific marker and was named HM1.24 antigen (2). Around the same 
time, another research group identified the BST2 gene, located on chromosome 
19p13.2, which showed variable expression in most normal tissues (3). Later, it was 
found that HM1.24 and BST2 were identical. In 2008, Neil et al. identified the cluster 
of differentiation 317 (CD317) in different cell lines, with the same structure as BST2. 
In some viral infections, these molecules tie up or “ tethers”  virions to the interior of 
infected cells, so it also acquired the name “ Tetherin” (4). The reported molecular 
weight of this protein is 30-36 kDa, but posttranslational modifications (e.g., 
ubiquitination) may raise the molecular weight to 70 kDa (5).   
1.2 BST2 Structure 
        The structure of BST2 protein consists of four parts: a cytoplasmic tail 
representing the amino terminal domain, a transmembrane domain, an extracellular 
domain and a glycophosphatidylinositol (GPI) anchor, which represents the protein’s 
carboxyl terminal (6). Being attached to the plasma membrane by two structurally 
different anchors gave BST2 an unusual topology (Figure 1.1). The presence of the 
GPI anchor infers that the localization of BST2 is within the plasma membrane 




Figure 1.1 The four components of BST2 structure. 
(Figure reproduced with permission from Dube M, Bego MG, Paquay C, Cohen EA. 
Retrovirology 2010, 7:114). 
 
        In the polarized epithelial cells, it was found that the distribution of BST2 is 
limited to the apical cell membrane, contrasting the pattern observed in B cells or in 
multiple myeloma, which consist of unpolarized cells (8). As shown in Figure 1.1, 
BST2 is assembled in dimers, through disulfide bonds. BST2 can also be found in 
the cytoplasm, mainly within the trans Golgi network (TGN), as a consequence of 
clathrin-mediated internalization from the surface, with data suggesting a continuous 
cycling of the protein between the cell membrane and the TGN (7).  
1.3 Physiological Roles of BST2 
        1.3.1 Pre-B cell growth: only one reported finding suggests a possible role of 




enhanced growth and proliferation of DW34, a murine pre-B cell line, when co-
cultured with BST2-positive BALB 3T3 cells, a murine fibroblast cell line. This report 
suggests that pre-B cells have a BST2 ligand for this cell-cell interaction (3).  
        1.3.2 Monocyte adhesion to endothelial cells: The expression of BST2 on 
the surfaces of many cells can be upregulated following interferon-gamma 
stimulation. Interferon-gamma, a type II interferon and a proinflammatory cytokine, is 
released by different immune cells as one of the host responses to infection or 
inflammation (9). Upon stimulation, the endothelial cells demonstrate an increased 
expression of BST2. BST2 thus acts as an adhesion molecule to monocytes and 
facilitates the migration of these cells out of the endothelium to the inflammatory site 
(10).  
        1.3.3 Antiviral role: As mentioned earlier, BST2, also known as Tetherin, has a 
demonstrated antiviral effect by binding virions particles to intracellular space, 
preventing viral budding. At first, this was observed in human immunodeficiency 
virus (HIV) which lacks the viral accessory protein, Vpu (4). However, later studies 
showed that the activity of this cellular restriction factor extends to other enveloped 
viruses, including retroviruses, filoviruses, herpesviruses and rhabdoviruses (11). 
        1.3.4 Immunomodulation: In response to an infection (or any nucleotide-
containing stimuli), the plasmacytoid dendritic cells (pDCs) secrete copious amount 
of proinflammatory cytokines and chemokines, through the stimulation of its Toll-like 
receptors 7 and 9 (TLR 7 and 9), including type I interferons (IFN I), tumor necrosis 
factor (TNF) alpha and Interleukin 6. In paracrine fashion, IFNs will upregulate BST2 




distinct receptor on the pDCs surface, called Immunoglobulin like transcript-7 (ILT7), 
resulting in the inhibition of IFN-alpha secretion on by pDCs (Figure 1.2). This 
interaction ensures the controlled secretion of cytokines and prevents adverse 
effects that could be associated with prolonged IFN stimulation (12).  
Figure 1.2 The interaction between BST2 and ILT7. 
This interaction will reduce the secretion on IFN by pDCs and limit the impact in the 
host (Figure reproduced with permission from Cao and Bover. Immunol Rev. 2010 
Mar; 234(1): 163–176). 
 
        The roles of BST2 in immunomodulation are not limited to the innate immune 
response. In experiments conducted by Urata et al., BST2-knock out mice 
demonstrated abnormal distribution of the viral nucleoprotein within the spleen. The 
dispersed virus was associated with defective T-cell priming and proliferation, with 
subsequent reduction in its effector functions (13). Moreover, the infected cells with 




dependent cellular cytotoxicity (ADCC). With BST2 silencing, these infected cells 
showed reduced sensitivity to this type of adaptive immune response (14). The 
“tethering” activity of BST2 is not restricted to the viral envelope. Instead, it can 
tether a variety of exosomes, which are extracellular vesicles that engage in many 
functions, including antigen presentation. By tethering exosomes, BST2 can play a 
role in managing the limit of engagement of these exosomes in antigen presentation 
and dendritic cell activation (15). In addition, this function could have an implication 
on the host immune response within the tumor microenvironment. Lastly, 
upregulation of BST2 in many cancers, e.g., breast cancer, ovarian cancer, and 
melanoma, can suppress IFN secretion by the pDCs through interactions with ILT7.  
This interaction may attenuate the immune response against the tumor and play a 
role in tolerance to malignant growths (12). BST2 immunomodulatory effects thus 
involve both innate and adaptive immunity.  
1.4 BST2 Distribution 
        1.4.1 Normal tissues: When it was first described, BST2 was thought to have 
a preferential expression on terminally differentiated B cells (2), a finding that led to 
the use of this surface marker as a target for monoclonal antibody-based 
immunotherapy against multiple myeloma. However, using tissue microarray, later 
research studied the extent of BST2 expression in various human tissues and found 
a broad range of organs that expressed this protein, including the liver, pancreas, 
lungs, kidneys, and vascular endothelium. The pattern of BST2 expression 
(constitutive vs inducible) and its level in tissues and organs were widely variable 




consensus with what has been reported in the Human Protein Atlas, which showed 
variable RNA and protein expression levels among the different organs and tissues 
(Figure 1.3 and 1.4) (17).   
Figure 1.3 BST2 RNA expression levels in various tissues and organs.  
Using RNA-Seq data from the Consensus dataset and the ovary as the tissue 





Figure 1.4 BST2 protein expression levels in various tissues and organs.    
(Image credit: Human Protein Atlas version 19.1, BST2, 
https://www.proteinatlas.org/ENSG00000130303-BST2/tissue) 
 
        1.4.2 Cancer tissues: The utilization of high-throughput molecular analysis 
techniques such as tissue microarrays and serial analysis of gene expression 
demonstrated the overexpression of BST2 in several solid and hematological 
malignancies at both the RNA and protein levels (18). During my study, I reviewed 
data from the Human Protein Atlas, which indicated that most examined cancer 
tissues stained positive with anti-human BST2 antibodies (Figure 1.5). The 
expression level was variable; high/moderate expression was observed in liver, 
breast, gastrointestinal and head and neck cancers, while low expression was noted 





Figure 1.5 BST2 protein expression levels in various cancers.                 
(Image credit: Human Protein Atlas version 19.1, BST2, 
https://www.proteinatlas.org/ENSG00000130303-BST2/pathology). 
 
        In breast cancer, a study found that the BST2 gene was upregulated in bone-
metastatic breast cancer cell line, compared to other primary and non-bone 
metastatic breast cancer cell lines. Moreover, BST2 serum levels were statistically 
significantly higher in patients with bone metastasis. Induced expression of BST2 in 
a primary breast cancer cell line enhanced its proliferation and migration abilities 
(20).  Another research group identified a demethylation process at the gene level 
that drives the overexpression of BST2 and enhances the metastatic abilities of the 





        In lung cancer, the upregulated expression of BST2 was observed in different 
lung cancer cell lines: small cell lung cancer, lung adenocarcinoma, and non-small 
cell lung carcinoma. However, the role of BST2 expression on lung carcinogenesis 
and/or metastasis must be elucidated. The commercially available anti-BST2 
monoclonal antibodies (MAbs) did not have a direct impact on the viability or 
proliferation of these cell lines, but were able to show both antibody-dependent 
cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity; these MAbs 
demonstrated significant effectiveness in reducing tumor size and growth in murine 
models (18). 
        In gastrointestinal cancers, BST2 overexpression was observed in cell lines 
representing esophageal, stomach and colorectal malignancies. BST2 silencing was 
associated with significant reduction in cell growth, and overexpressing BST2 protein 
in a BST2-deficient colorectal cancer cell line significantly enhances its growth. 
Furthermore, the expression of BST2 was correlated with poorer survival among 
patients with gastrointestinal cancers (22). 
        In head and neck cancers, many gene expression databases indicated 
overexpression of BST2. Clinical data from patients with head and neck squamous 
cell carcinoma and high BST2 expression showed poor survival, compared to 
patients with low BST2 expression (23). Moreover, BST2 silencing rendered 
nasopharyngeal cancer cells sensitive to cisplatin and halted its resistance to 
platinum therapy (24). 
        Lastly, in hematological malignancies, BST2 (or HM1.24) was first described as 




expressed on terminally differentiated B cells. More than 80,000 molecules of BST2 
could be identified on the surface of a single myeloma cell (2). Although the 
functional role of BST2 in multiple myeloma has not been identified yet, the 
overexpression of this surface protein and the need for new therapeutic approaches 
in treating this malignancy made BST2 a potential therapeutic target, using MAbs. 
Initial preclinical studies and mouse models demonstrated the effectiveness of these 
anti-BST2 MAbs in limiting the tumor burden, mainly through ADCC. Consequently, 
a phase I/II clinical study was initiated to test the safety and effectiveness of these 
MAbs as a therapeutic agent in patients with relapsed or refractory multiple 
myeloma. The response rate was relatively low, and the study was terminated, 
despite manageable adverse events (25). The expression of BST2 on the surface of 
other malignant blood cells, including mature B lymphocytes, has been evaluated as 
well. Using patients’ samples, BST2 was expressed in chronic lymphocytic leukemia 
and mantle cell lymphoma, making BST2 a potential therapeutic target in other 
subclasses of malignancies (26).  
        To conclude, BST2 has been extensively investigated and studied for its 
protumor roles. It has been used as a target for new therapeutic approaches to treat 








1.5 BST2 Isoforms 
        Different research groups described various BST2 isoforms resulting from 
alternative splicing. In 2005, a Japanese group identified three splice variants of 
BST2: BST2-D, BST2-H and BST2-HS (patent no. JP2004173767)(27). These 
variants differed in protein length and amino acid sequence. The isoforms were 
defined as followed: BST2-D (long isoform) is 180 amino acids, BST2-H (medium 
isoform) is 158 amino acids, and BST2-HS (short isoform) is only 100 amino acids 
(Figure 1.6). The functional significance of these variants and whether any of them 
are cancer-specific has not been studied and elucidation of their roles is warranted 
(27). 
Figure 1.6 BST2 Isoforms as described by patent JP2004173767. 
An illustration of the three isoforms described by the group of Japanese scientists: 
BST2-D (long isoform) with 180 amino acids, BST2-H (medium isoform) with 158 




        In 2012, Cocka et al. described two isoforms of Tetherin/BST2, a long isoform 
and a short isoform (28). As a consequence of alternative translation initiation, the 
short isoform was unrelated to that described earlier by the Japanese patent; it 
lacked the first 12 amino acids that present in the long isoform (Figure 1.7).  
Figure 1.7 BST2 Isoforms as described by Cocka LJ, Bates P.                          
An illustration of the two isoforms described by Cocka et al. The long BST2 isoform 
has 180 amino acids and the short BST2 isoform has 168 amino acids, lacking the 
first 12 amino acids. 
 
        Cocka et al. demonstrated that these isoforms were associated with distinct 
antiviral and signaling activities. BST2 isoforms may merge with a similar or different 
isoform, forming homo- or heterodimers, respectively. Mechanisms that govern 
interactions between these isoforms to build dimers are not well understood, but the 




roles of BST2. Although both isoforms have the ability to restrict viral budding and 
release, through tethering the viral particles, the short isoform is more resistant to 
Vpu-mediated HIV antagonism. BST2 is a known activator of the Nuclear Factor-
Kappa B (NF-kappa B) pathway, a signaling pathway involved in many biological 
activities, including the regulation of immune responses and inflammation (28). 
Unregulated activation of this pathway has been associated with carcinogenesis 
processes, including proliferation, migration, and invasion (29). The long BST2 
isoform appeared as a potent activator of the NF-kappa B pathway, while the short 
isoform displayed no activation. Moreover, the short isoform exhibited an ability to 
modulate the effect of the long isoform on this pathway, and heterodimers 
demonstrated reduced NF-kappa B signaling. Increasing the number of short BST2 
isoforms, relative to the long isoform, also diminished the activity of this pathway. 
This suggests the inhibitory role of the short isoform in regulating NF-kappa B 
pathway signaling by the long BST2 isoform (28). 
1.6 Hypothesis  
        Since my interest lies in cancer therapy, I decided to further study the isoforms 
proposed and patented by Jun Ohkawa and Yumiko Kakogawa. By collaborating 
with their group, our lab obtained the expression plasmids containing BST2-H 
(medium) isoform. The expression vector of the full-length BST2 (long BST2 
isoform) was commercially available. HEK293 cells were previously transfected with 
these plasmids, and BST2 expression was confirmed via western blot analysis. 
Moreover, HEK293 cell lines expressing either long BST2 isoform (HEK293-long) or 




(26F8) that was previously generated in our laboratory. Later, using a T-cell line with 
the nuclear factor of activated T cells - green fluorescent protein (NFAT-GFP) 
construct, our lab successfully integrated a human immunoglobulin like transcript 7 
(ILT7) – Fc epsilon RI gamma protein (FCeRIy) complex and created a report cell 
line that expresses GFP upon the interaction between ILT7 & and its ligand, BST2 
(30). HEK293-long cells were able to activate NFAT, which resulted in GFP 
expression, while HEK293-medium cells failed to activate the reporter cell system. 
        In a prior experiment, using the same reported cell system, co-culturing the 
reporter cells with human breast carcinoma cell lines MDA-MB-468, MCF7, and 
T47D induced GFP expression. In contrast, other non-malignant cell lines known to 
express BST2 , such as HEK293, Vero and CHO, failed to induce GFP expression 
when co-cultured with the same reporter cells (31). Taken together, along with what 
has been described about the BST2 isoforms and their roles in activating or 
modulating NF-kappa B pathway, we hypothesized that: 
- The long-reported isoform of BST2 (BST2 long) is preferentially expressed on 
cancerous cells and might be responsible for modulating the immune 
microenvironment by interacting with infiltrating immune cells like pDCs, and  








1.7 Specific Aims 
        Specific Aim 1: Generate anti-human-BST2 MAbs via hybridoma technology, 
specifically targeting the long BST2 isoform.  
        Specific Aim 2: Characterize the specificity of the antibodies and perform PK 
analysis of the selected purified clones to choose the best MAb candidates for 
immunohistochemistry (IHC) and for potential future therapeutic use. 
        Specific Aim 3: Use the generated anti-human-BST2 MAb candidates to 
analyze the expression of the long BST2 isoform in cancer and in normal tissues 
with flow cytometry staining and IHC.  
        Specific Aim 4: Study the function of BST2 in the T47D breast cancer cell line. 












2. Materials and Methods 
2.1 Antigen for Mice Immunization 
        A synthetic peptide was used as the antigen for immunization. It was produced 
by ThermoFisher Scientific in two forms, peptide alone and keyhole limpet 
hemocyanin (KLH)-conjugated peptide. 
        2.1.1 Injection dose preparation:  The immunization doses were emulsified 
using incomplete Freund Adjuvant (IFA - InvivoGen). Using a 28-gauge insulin 
syringe, equal volumes of BST2-Long (D) peptide and IFA were mixed vigorously for 
several minutes until a white emulsion with maximum stability formed. Each 
emulsified 20 ul dose contained 10 ug of BST2-D peptide-KLH. On the three 
additional weekly boost injections, the peptide dose was raised to 15 ug. 
2.2 Animal Work 
        All animal experiments were conducted according to the University of Texas 
MD Anderson Cancer Center’s Institutional Animal Care and Use Committee 
(IACUC) guidelines and approved protocols (Protocol IACUC 00000620-RN02). 
Female BALB/c mice were purchased from Jackson Laboratories (Bar Harbor, ME). 
        2.2.1 Tail vein blood collection: 50 ul of blood samples were collected from 
the lateral tail vein. It was punctured with a 28-gauge insulin needle while mice were 
restrained. After coagulation, serum was separated. An equal volume of glycerol 
was added to the serum and samples were stored at -20oC. A total of three serum 
samples were collected on day 0 (preimmunization), day 14 (after 5 injections) and 




        2.2.2 Immunization route and schedule:  Three 6-8-week-old female BALB/c 
mice were immunized. On day 0, a 50 ul pre-immunization serum sample was 
collected from each mouse. Injections were given through a footpad route at three-
day intervals (Day 0, 3, 6, 9, and 12) for a total of five injections. Three additional 
weekly injections were given to boost the immune response (Day 15, 22 and 29) to 
complete a grand total of 8 injections. 
        2.2.3 Euthanasia: Following MD Anderson IACUC guidelines, the mice were 
exposed to carbon dioxide (CO2) in the CO2 chamber, at a flow rate of 2 L/min for six 
minutes. Cervical dislocation was performed as a secondary euthanasia method. 
        2.2.4 Harvesting the popliteal lymph nodes:  After euthanasia, the mice were 
whipped with ethanol 70%, transferred to the tissue culture hood and pinned into a 
dissection board. Using scissors, a midline incision was made, and the fur was 
removed. The popliteal lymph node, located at the popliteal fossa and embedded in 
adipose tissue, was carefully excised to preserve the node structure and integrity. 
Only the popliteal lymph nodes draining the injected footpad were collected and 
placed in a petri dish with RPMI 1640 medium.  
2.3 Hybridoma Generation  
        The two mice with the highest serum titers were selected for fusion while the 
third mouse was reserved as a backup. The following materials and media were 
used: 
- HAT supplement (50x) [Sigma]: this mixture of hypoxanthine (5 mM), 




selection medium against unfused or self-fused SP2/0 myeloma cells. As a 
folic acid inhibitor, aminopterin blocks the de novo pathway for nucleoside 
synthesis in SP2/0 myeloma cells, which lack the hypoxanthine-guanine 
phosphoribosyl transferase (HGPRT) enzyme and, as such, they lose the 
ability to utilize nucleotides provided by the salvage pathway.  
- RPMI 1640 medium [Sigma]: used to prepare the selection medium and 
washing cells. 
- Polyethylene glycol (PEG 1450): used as the fusing agent in the hybridoma 
technique. On the day of fusion, 1 ml vial of PEG was maintained at 37oC until 
the fusion step. 
- Rat Supplement (RSCM), used as a growth supplement for the hybridomas.  
- Fetal Bovine Serum (FBS). 
The selection media consists of RPMI – 1640 with 10% FBS, 2% HAT supplement 
50x, and 3% RSCM. The following cells were used during the hybridoma generation 
experiment: 
- SP2/0: The myeloma cell line SP2/0 was selected as a partner cell line for 
hybridoma generation. One week before fusion, SP2/0 murine myeloma cells 
were thawed, maintained in RPMI 1640 and 10% FBS and expanded to 1*108 
cells in petri dishes. On the day of fusion, cells were collected in 50 ml tubes, 
centrifuged, and washed twice with RPMI medium before the fusion process. 
- Murine lymphocytes: These cells were collected from the excised popliteal 
lymph nodes. These lymph nodes were dissected with scissors and forced 




The collected lymphocytes were centrifuged (1000 RPM for three minutes) 
and washed twice with RPMI medium before the fusion process. 
        With a cell-counting hemocytometer, both SP2/0 and murine lymphocytes 
were counted and combined in a ratio of 1:2 (Sp2/0 to lymphocytes) in a 50 ml 
tube. The tube was centrifuged at 1000 RPM for five minutes to pack the cells 
together and prepare them for the fusion. After discarding the supernatant and 
loosening the cell pellet, 1 ml prewarmed (37oC) PEG was added to the tube 
while swirling for 45 seconds. The reaction was stopped by adding 24 ml 
prewarmed (37oC) RPMI medium. Fused cells were centrifuged at 1000 RPM for 
5 minutes, supernatant was discarded, and the cell pellet was loosened by gentle 
tapping and transferred to the selection medium. Hybridoma cells suspension 
was distributed into six 96 MW plates (150 ul/well) and incubated at 37 oC, 5% 
CO2.  
2.4 Hybridomas Colony Pickup 
        Seven days after fusion, enzyme-linked immunosorbent assay (ELISA) was 
performed to detect positive wells containing hybridoma colonies. Following results, 
the procedure of “single colonies pickup” was performed in two phases at a one-
week interval. Well-demarcated colonies were identified, collected with a 2 ul pipette, 
and transferred into a 96-well plate containing hypoxanthine and thymidine (HT) 
selection media. These colonies were incubated at 37oC and 5% CO2.  A total of 563 
colonies were picked up in two phases: 




- Phase II: 279 colonies 
After two days, primary screening was performed via ELISA. 
2.5 ELISA screening 
        To select the hybridomas capable of producing specific monoclonal antibodies 
against the Long BST2 peptide, ELISA was performed. ELISA plates were coated 
with a 100-ul coating buffer, containing the BST2-D peptide in a concentration of 1 
ug/ml, and incubated overnight at 4oC. The next day, ELISA plates were washed 
three times with PBSt (PBS containing 0.05% v/v Tween®-20) and blocked with 100 
ul of blocking buffer (PBS, 1% w/v BSA).  After an hour of blocking at room 
temperature, 50 ul supernatant from each of the 563 colonies were added to 
individual wells as the primary antibodies. The anti-BST2 MAb (clone 26F8) 
[eBioscience] was used as a positive control and blank wells with secondary 
antibody only were performed in triplicates. After one hour of incubation, three 
washes followed. 50 ul of secondary antibody, goat anti-mouse IgG, HRP 
conjugated (1:2000) was added to each well and incubated for one hour. After 
washing four times, the substrate solution (TMB) was added to each well and 
incubated for 30 minutes. The reaction was stopped with H2SO4 0.2N and the OD 
absorbance values were read at 450 nm. This screening step was repeated twice. 
26 hybridomas were transferred to 24-well plates containing HT-medium, and 
incubated for 4-7 days at 37oC, 5% CO2. 2 ml supernatant was collected from each 




          For ELISA dilution assay, ELISA plates were coated overnight with 0.5 ug/ml 
BST2-D peptide; serial dilutions of the pre-collected supernatants were used as 
primary antibodies (undiluted, 1/15, 1/225 and 1/3375). The clones with the highest 
OD 450 nm signal were selected to proceed to the next screening assays. 
        For cell-based ELISA, plates were loaded with parental HEK293 cells, HEK293 
expressing long BST2 isoform, or HEK293 expressing medium BST2 isoform at a 
density of 15 x 104/50 ul per well and dried at RT overnight. ELISA was performed 
as described before using 50 ul supernatant from each clone.        
2.6 Flow Cytometry Staining and Analysis (FACS) 
      For flow cytometry assays, cells were detached using 0.05% trypsin-EDTA, 
counted, washed, and resuspend with FACS Buffer (PBS, 2% FBS,2 mM EDTA).     
2x105 cells in 100 ul/well were placed in a U-bottom 96-well plate and centrifuged 
(1000 RPM/ 3 min/ 4oC). The buffer was discarded and 100 ul of the previously 
collected supernatants were added to the wells and incubated on ice for 30 minutes. 
After incubation, the plate was washed three times with FACS buffer and 50 ul of 
diluted (1/250) secondary antibody (donkey anti-mouse allophycocyanin (APC) 
conjugated) were added to the wells and incubated on ice for 20 minutes while 
protected from light. The final wash was repeated four times, and the samples were 
transferred and analyzed at the South Campus Flow Cytometry & Cell Sorting Core 
Laboratory at MD Anderson Cancer Center. FACS data were analyzed with 
FlowJo™ Software-for Windows (Version 10.6.1. Ashland, OR: Becton, Dickinson 




2.7 Hybridoma Subcloning 
        The hybridoma clone (LA5) was expanded in 24 well plates with HT-based 
media for three days. With 70% confluency and viability of over 90 %, cells were 
counted (with a hemocytometer), and diluted to a concentration of 5 cells/ml. Using a 
multichannel pipet, 200 ul/well were added in a 96-well tissue culture plate. The 
hybridomas were cultured for 7-10 days at 37oC, 5% CO2. As described before, 
screening was performed by ELISA against the long BST2 peptide. The absorbance 
values were read at 450 OD, and the two wells with the highest OD signals were 
maintained and transferred into a 24-well plate. Two days later, the HT-based 
medium was substituted with RPMI-FBS 10% and the clones were transferred to 
T25. Further expansion into T75 was performed for the purpose of MAb purification. 
2.8 Purification and Concentration of MAbs 
        After expansion and incubation of the selected hybridomas, 300 ml of the MAb-
rich supernatants were collected, centrifuged, and filtered through 0.45-micron 
membrane. MAbs were purified via Protein A affinity chromatography procedure (GE 
Healthcare MabSelect SuRe Cat # 17-5438-08). After the assembly and washing of 
purification columns, supernatant was neutralized with 1 M Tris-HCl (pH 9) buffer 
and allowed to run in the columns twice. The captured antibodies were eluted from 
the columns, using elution buffer (0.1M glycine-HCl, pH 3) and the concentration 
was measured in the Nanodrop. An overnight dialysis in PBS (Fisherbrand 
Regenerated Cellulose Dialysis Tubing) was performed and the concentrated anti- 
long BST2 (clone LA5) MAb (1 mg/ml) was collected and stored at 4°C, ready for 




2.9 Antibody Isotyping 
        The isotype of the generated MAb was determined using Mouse Monoclonal 
Antibody Isotyping Reagents [Sigma-Aldrich, Catalog Number ISO2] following 
manufacturer recommendations. It is based on the ELISA technique. 
2.10 Affinity Testing 
        Using the Octet RED384 System, the kinetics of the generated MAb were 
tested and compared to the anti-BST2 (clone26F8) MAbs [eBioscience]. Developed 
by FORTEBIO and based on Bio-Layer Interferometry (BLI) technology, the Octet 
RED384 system can measure the affinity constant (KD) of an antibody with a range 
of 1 mM to 5 pM (32). The following materials and conditions were applied to the 
experiments: 
• Sensor type: AMC (Anti-mouse IgG Fc capture) biosensor (part number 18-
5088, ForteBIO). 
• 10x Kinetics buffer: 10mM Phosphate, 150 mM NaCl, 0.02% Tween 20, 
0.05% Sodium Azide, 1 mg/mL BSA (pH 7.4) (part number 18-5060, 
ForteBIO). 
• Monoclonal antibodies: clones LA5 and 26F8 at a concentration of 5 ug/ml. 
• Recombinant human BST2 protein (Catalog number 13370-H07H, Sino 
Biological). 
• BST2 protein concentrations: a serial dilution of concentrations was used to 




62.5, 31.25 and 15.625 nanomolar). The calculated nanomolar concentrations 
were based on the molecular weight of the BST2 protein. 
• Assay steps and time: following the guidelines, Table 1 describe the steps of 
the assay and time spent in each step. 
• Data Analysis: I used Octet Data Acquisition software V10.x to analyze the 
results. I used a 1:1 binding model, where both the association and 
dissociation phases were taken into consideration. Results were obtained 
after global fitting from the various concentrations of protein.  
 
Table 1 Steps and times of the kinetics assay using the Octet RED384 system 
Assay step Step name Assay time (seconds) 
1 Baseline 60 
2 Loading 300 
3 Baseline 300 
4 Association 300 
5 Dissociation 300 











        A specificity assay was performed and analyzed via flow cytometry staining of 
MM1, a multiple myeloma cell line. In this assay, changes in the binding of the LA5 
MAb to the BST2 receptor expressed on MM1 cell lines were assessed after: 
- 10-minute preincubation with BST2 protein (5ug/ml).   
- 10-minute preincubation with Spartan protein (5ug/ml). 
        Results were compared to the anti-BST2 Clone 26F8 MAb and mouse IgG1 
isotype control (eBioscience, catalog #14-4714-82). FACS data was analyzed with 
FlowJo™ Software - for Windows (Version 10.6.1. Ashland, OR: Becton, Dickinson 
and Company; 2020). 
2.12 Cell Lines and Media 
The following cell lines were used: 
- B-LCL: a non-malignant B cell line that has been infected with Epstein-Barr 
virus to provide a continuous source of primary B cells [Astrarte Biologics]. 
These cells were maintained and expanded in RPMI 1640 medium, 
supplemented with 10% FBS. 
- MM1: a multiple myeloma cell line that was generously provided by Dr. 
Robert Orlowski’s laboratory. It represents malignant B-lymphoblasts that 
grow in suspension and as lightly attached cells. These cells were maintained 
and expanded in RPMI 1640 medium, supplemented with 10% FBS. 
- U266: a multiple myeloma cell line that was generously provided by Dr. 




grow in suspension. These cells were maintained and expanded in RPMI 
1640 medium, supplemented with 10% FBS. 
- MCF-10A: a nonmalignant epithelial breast tissue cell line [ATCC]. This cell 
line grows in a special medium that was purchased from Lonza/Clonetics as a 
kit [MEGM, Kit Catalog No. CC-3150].  
- MDA-MB-231: human breast adenocarcinoma cell line that was generously 
provided by Dr. Ze Tian. These cells grow in RPMI-1640 based medium, 
supplemented with 10% FBS. 
- MCF7: human breast adenocarcinoma cell line that was generously provided 
by Dr. Ze Tian. These cells grow in Dulbecco’s Modified Eagle’s medium, 
supplemented with 10% FBS. 
- T47D: human breast ductal epithelial carcinoma. Stocks of this cell line were 
available in our lab. These cells grow in RPMI-1640 based medium, 
supplemented with 10% FBS. 
2.13 Immunocytochemistry and Immunohistochemistry 
        The immunocytochemistry (ICC) assays on transduced cells overexpressing 
BST2 isoforms were performed by the Research Histology Core Laboratory (RHCL) 
at MD Anderson Cancer Center. Paraffin blocks were prepared from cell pellets of 
HEK293, HEK293 BST2-long and HEK293 BST2-medium.  Briefly, all cell pellets 
were fixed in 4% formalin for 10 minutes, centrifuged and washed with PBS and 
resuspended in fresh PBS prior to submission to the Core. The pellets were 
embedded in paraffin with standard techniques. 5 μm sections were cut and stained 




BST2 was performed with the DAB kit (DAKO). Hydrogen peroxide was used to 
deactivate intrinsic peroxidase. Antigen retrieval was performed in a water bath 
using citrate-EDTA buffer (10mM citric acid, 2mM EDTA, 0.05% Tween 20, pH 6.2). 
Sections were incubated with undiluted supernatant containing secreted anti-BST2 
antibodies or with a purified antibody. As negative controls, immunostaining was 
performed by incubating samples with PBS instead of the primary antibody. After 
staining with DAB and counterstaining with hematoxylin, the slides were recorded 
using a digital camera. The immunohistochemistry assays on human breast cancer 
tissues was performed at the laboratory of Molecular Pathology, Hospital El Cruce, 
Florencio Varela, Buenos Aires, Argentina (Dr. Inés Bravo). 
2.14 BST2 Silencing Using Short Hairpin RNA (shRNA) 
        The Functional Genomic Core (FGC), at MD Anderson Cancer Center, carries 
a human shRNA library that targets the entire human genome, including five 
plasmids that target human BST2. Through collaboration with the FGC, the five 
different BST2-silencing plasmids (as well as a non-silencing control) were 
introduced into E. coli strain DH5α. This strain harboring a plasmid was inoculated 
into an ampicillin-containing LB media and cultured at 37°C in a shaker incubator 
overnight. The plasmids were extracted with QIAGEN Plasmid Plus Midi Kit. HEK-
293T cells were used to generate shRNA-containing lentivirus using a third-
generation lentiviral system. jetPRIME reagent was used as a transfection reagent 
[Polyplus transfection, reference number 114-15]. Lentivirus-containing supernatants 
were collected 24- and 48-hours post- transfection and concentrated [LentiFuge 




        2.14.1 Transduction of the cell lines: The first step in transduction was to set 
the experiment conditions. The following assays were performed: 
- Lentiviral transduction titration assay. 
- Polybrene toxicity assay. 
- Puromycin titration assay. 
        2 - 3 * 10^5 cells were seeded per well in a 6-well plate. 24 hours later, 40 ul of 
4x lentivirus vector was added per well, which was based on the multiplicity of 
infection (MOI) of 5. To enhance transduction, polybrene was added in a 
concentration of 8 ul/ml. 48 hours post-transduction, 2 ug/ml Puromycin was added 
to each well as a selective antibiotic. 10 days post-transduction, BST2 expression 
was assessed, using western blot and flowcytometry staining.  
2.15 Cell Viability Assay 
        Cell viability assay was performed on cells following BST2 silencing, using 
CellTiter-Glo Luminescent (Promega, Catalog # G7570), following manufacturer 
protocol.  
2.16 Cell Proliferation Assay 
        Cell proliferation assay was performed on cells following BST2 silencing using 
XTT - Cell Proliferation Assay Kit (ThermoFisher Scientific, Catalog # X12223).  
2.17 Reverse Phase Protein Array (RPPA) 
        Samples of non-silenced and silenced BST2 cell lines were sent to the Reverse 




proteomics studies. Cell pellets were prepared at our lab and stored at -80oC. 
Protein extraction was performed at the RPPA core lab. 
2.18 Statistical Analysis 
        Statistical analyses were performed with FlowJo™ Software – for Windows 
(Version 10.6.1. Ashland, OR: Becton, Dickinson and Company; 2020) and/or 
GraphPad Prism Software version 7.00 (La Jolla, California) for Windows. Data sets 
were analyzed with Mann-Whitney U Test, Student T-Test or ANOVA test.  
        P values for comparisons between groups were determined and a value of less 















3.1 Generating the Long BST2 Isoform Peptide, Immunization and Serum Titer 
        To generate MAbs specifically against the long isoform of BST2 (BST2-D), a 
unique sequence should be identified. By comparing the amino acid sequences of 
the different isoforms of BST2, we identified a section of the extracellular domain of 
the BST2 protein found exclusively in the long isoform and not in the other isoforms 
of BST2. This peptide spanned between amino acids 133 and 156 on the long 
isoform of the BST2, the number of residues being 24. The amino acid sequence of 
the generated peptide was EVERLRRENQVLSVRIADKKYYPS and had the 
following molecular characteristics: 
- Molecular weight: 2949.32 g/mol 
- Isoelectric point: pH 10 
- Solubility: Good water solubility 
        Given the small size of peptide, the use of KLH as a carrier protein was 
selected to ensure an adequate immune response can be elicited after mice 
immunization. 
        Three female Balb /c mice 6-8 weeks old were selected for immunization. Pre-
immunization samples were collected and a series if footpad injections were 




Figure 3.1 Immunization Schedule. Three mice were immunized every three days 
for the first five doses and then weekly for the three boosts doses. Blood samples 
were drawn at indicated times, following IACUC protocol 00000620-RN02. 
        
        Reasons for choosing the footpad route were the establishment of an easy and 
quick way to monitor the host immune response and the ability to collect a higher 
population of specifically-responding B lymphocytes to be used in the hybridoma 
technique, by harvesting the popliteal lymph nodes (33). To measure the immune 
response, serum titration was performed after five injections, using the ELISA 
technique. Results showed insufficient immune response. After the third weekly 
booster dose, serum titration assay was repeated and revealed an adequate 
immune response in each mouse to proceed with hybridoma generation by chemical 
fusion (Figure 3.2). Mice A and B were selected for the hybridoma experiment, while 





















































































Figure 3.2 Immune response.  Titration curves compare the immune response 
from the immunized mice (A, B and C) after five injections and then after eight 
injections. The pre-immune serum sample was used as a control. Plates were 
coated with BST2 peptide alone. 
3.2 Fusion, Hybridoma Generation and ELISA Screening  
        With an optimal serum titer observed two days after the last booster dose, 
fusion was performed on day 32. SP2/0 cells were selected as a partner cell line for 
hybridoma generation; these cells do not secrete immunoglobulins and are sensitive 
to the selection media HAT (hypoxanthine-aminopterin-thymidine). Within two weeks 
after fusion, I was able to identify 563 hybridomas in six 96-well plates. Initial ELISA 
screening of the 563 colonies generated by cell fusion revealed the presence of 26 
clones with antibody-containing supernatant that is reactive against the peptide of 
interest (BST2-D peptide). To choose the best candidates among the selected 
colonies in terms of the productivity and affinity of the generated MAbs, a dilution 
assay was performed with the positive supernatants using the ELISA technique. The 
16 clones with the highest OD 450 nm signal were chosen to proceed to the next 
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Figure 3.3 Dilution assay. 26 positive clones were tested at serial dilutions as 
described under the methods. Sixteen clones with the highest OD450 nm signal (red 
squares) have been selected for further characterization. LA1-LA16 were clones 
picked at the first round of colony pickup; clones BM1-BM10 were picked at the 
second round of colony pickup. PC (positive control) was anti-BST2 MAb (clone 
26F8) 1 ug/ml which recognizes all isoforms. Plates were coated with BST2 peptide 
alone. 
 
3.3 Cell-Based ELISA 
        Cell-based ELISA confirmed the ability of the generated hybridomas to secrete 
MAbs that specifically bind to the long isoform of BST2 (BST2-D) with minimal or no 
binding to the medium isoform (BST2-H). For that purpose, we used HEK293 cell 
line and transfectants previously generated in our laboratory. In summary: 
- HEK293 (parental): These cells demonstrate a very low expression of BST2, 
and it is inducible using IFN. 
- HEK293 WT-BST2 (or HEK293 long): the HEK293 cells are transfected with a 
plasmid of the full length BST2, which is identical to the long isoform of BST2. 
This transfectant constitutively expresses BST2 (non-inducible). A full length 
BST2 vector was commercially available. 
- HEK293-H (or HEK293 medium): HEK293 cell line transfected with a plasmid 




obtained through collaboration with Dr. Naoko Arai’s laboratory, (SBI Biotech 
Co., Ltd., Ginkgo Biomedical Research Institute, Kawasaki 216-0001, Japan). 
        Both transfectants were recognized by anti-BST2 (26F8) MAb [eBioscience]. I 
selected the colonies that demonstrated maximum binding to the HEK293 cells 
expressing the long isoform (HEK293 BST2-long) and minimal interactions with the 
HEK293 parental or the HEK293 BST2-medium transfectant. The best three clones 
that met these criteria, reflected by their associated OD 450 signals, were chosen for 
the last stage of testing (Figure 3.4). LA1, LA5 and BM7 showed the best 
combination of high OD 450 signals with HEK293 BST2-long transfectants AND low 
signals with HEK293 BST2-medium and HEK293 cell lines, suggesting the 
capabilities of these clones to produce antibodies with high affinity to the long 











Figure 3.4 Cell-based ELISA.  
Screening of selected supernatants occurred using HEK293 cell lines expressing 
different BST2 isoforms as indicated in the legend. Three clones (LA1, LA5 and 
BM7) were selected (marked with red arrows) based on specified criteria: high OD 
450 signals with HEK293/BST2 long transfectants AND low signals with 
HEK293/BST2 medium and HEK293 parental cell lines. 
 
3.4 Flowcytometry Staining of HEK293 Cell Lines         
        To confirm the results of the cell-based ELISA, staining of the HEK293 
transfectants was examined by flow cytometry, using previously collected 
supernatants. Three clones (LA1, LA5 and BM7) generated the highest staining of 
HEK293-long cells that express the long isoform of BST2 and a weaker (or no) 




Figure 3.5 Flowcytometry staining of the HEK293 cell lines.  
Using supernatants collected from the three selected clones (LA1, LA5, and BM7), 
the data showed maximum mean fluorescence staining of the HEK293-long 
transfectant and minimum staining of the other cell lines. For the control, only a 
secondary antibody (donkey anti-mouse APC conjugated) was used. 
 
        Flowcytometry analysis revealed that LA1 supernatant stained 70.9% of 
HEK293-long cells, with minimal staining of HEK293-medium transfectant and the 
HEK293 cells (1.6 and 2.2%, respectively). Using supernatant from BM7 was 
associated with less staining of the HEK293-long cells (39.8%) and minimum 




respectively). Compared to BM7, the LA5 supernatant was associated with a better 
staining of HEK293-long, with a percentage of 58.3% and comparable results for the 
HEK293 – medium and the parental (0.05% and 0.1%, respectively). Based on 
these results, LA5 clone demonstrated the best ability to generate MAbs with high 
affinity to the long isoform of BST2, with minimum interaction to the other isoform. It 
was therefore selected for subcloning and purification to ensure the purity of the 
clone selected and the consistency of the MAbs secreted. 
        After the purification and production of the anti-BST2 long MAb (clone LA5), at 
a concentration of 1 mg/ml, flow cytometry staining was repeated with the purified 
LA5 MAb and compared with the commercially available anti-BST2 (clone 26F8) 
MAb (Figure 3.6). The results from FACS staining confirmed the ability of the 
generated MAb to bind selectively to the transfectant expressing the long isoform of 
BST2 and not the medium isoform (49.8% and 0.28%, respectively). The results also 
demonstrated the differences between the generated clones LA5 and 26F8 MAbs, in 







Figure 3.6. Comparison between clones LA5 and clone 26F8.   
Flow cytometry staining of HEK293 long and HEK293 medium transfectants, using 
1ug/ml of clones (LA5) and anti-BST2 (26F8) MAbs. This figure demonstrates the 
specificity of the generated antibody (LA5) to selectively bind to the long isoform. In 
contrast, the 26F8 MAb recognized both isoforms. APC conjugated secondary 
antibody alone was used as controls. 










        Figure 3.7 summarizes the processes and various screenings that led to the 
production of purified and concentrated Anti-BST2 long (Clone LA5) MAb. 
 
Figure 3.7 Anti-BST2-long MAb Screening Funnel.  
The diagram shows the various screening steps performed after the generation of 









3.5 Antibody Isotype 
        After subcloning and purification of the single clone (LA5), several experiments 
were performed on the anti-BST2-long MAb in order to define its characteristics. 
Using ELISA technique, isotype testing revealed the highest OD 450 signal with 
IgG1. The test was negative for IgM (non-significant low reactivity shown), IgG2a, 
IgG2b, IgG3 and IgA (Figure 3.8). Given these results, IgG1 isotype, commercially 
available clone was selected as the isotype control for all the experiments. 
 
Figure 3.8 Isotype ELISA test. Isotype of clone LA5 was determined by an ELISA 






3.6 Antibody Affinity 
        The binding kinetics of the anti-BST2-long MAb (clone LA5) was assessed, 
using Octet RED384 platform system. Briefly, antibodies were captured, as 
described under methods, by specific biosensors that bind the Fc region of the 
antibody. Based on multiple experiments and the standard operations procedures in 
our laboratory,   a global fit of the data (R^2 = 0.9902) revealed an association rate 
constant (Ka) of 2.0 +/- 0.019 * E+5 1/Ms and a dissociation rate constant (Kdis) of 
9.21 +/- 0.12 * E-4 1/s. The calculated equilibrium dissociation constant (KD) of the 
LA5 MAb was 4.61 +/- 0.074 * E-9 M, a nanomolar value (Figure 3.9). 
Figure 3.9 Determination of Ka, Kdis and KD for LA5-antigen binding. 
The binding kinetics of anti-BST2-long clone LA5 (5 ug/ml) and BST2 protein at 





        Comparing the kinetics of both anti-BST2 clone 26F8 MAb and LA5, a 
difference of one order of magnitude was observed, indicating that our new 
generated antibody exhibits a better affinity (in the nanomolar range) than the 
previously generated 26F8 MAb. With a 1:1 binding model and a global fit of the 
data (R^2 = 0.9883), the association rate constant (Ka) was 3.86 +/- 0.058 * E+4 
1/Ms and the dissociation rate constant (Kdis) was 1.32 +/- 0.019 * E-3 1/s. The 
calculated KD of clone 26Fb was 3.42 +/- 0.072 * E-8 molar (Figure 3.10). 
Figure 3.10 Determination of Ka, Kdis and KD for 26F8-antigen binding.  
The binding kinetics of anti-BST2 clone 26F8 (5 ug/ml) and BST2 protein at various 







3.7 Antibody Specificity  
        As part of the characterization of the selected clone (LA5), we analyzed the 
antibody specificity using the approach of flow cytometry staining of MM1, a multiple 
myeloma cell line that constitutively expresses BST2. Staining of MM1 was 
assessed at different conditions, by directly incubating MM1 with LA5 or blocking the 
antibody binding to the cells through preincubation with recombinant BST2 protein, 
that contains the epitope used to generate the antibody. Appropriate negative control 
was performed by using an irrelevant protein for blocking. Anti-BST2-long (clone 
LA5) was pre-incubated with BST2 protein for 10 minutes, before being transferred 
to the U-bottom wells containing MM1 cells. Using the BST2 protein-preincubated 
MAb, the staining percentage of the MM1 cells was reduced from 85.2% to 5.01% 
(Figure 3.10). This significant reduction suggested the strong specific binding of the 
MAb to the BST2 protein, leaving less free MAb available for binding to the BST2 
receptors on the MM1 cells. Alternatively, Spartan protein, or SprT-like domain-
containing protein, a human DNA-binding metalloprotease with 489 amino acid 
length and involved in the response to DNA replication errors (34, 35) was used as 
an irrelevant protein. Preincubating LA5 MAb with this protein for 10 minutes did not 
change the percentage of staining, compared with the direct incubation of the MAb 
with MM1 cells (85.2% and 83.9%, respectively) (Figure 3.11). The same pattern 
was observed with the use of anti-BST2 (26F8) MAb; the percentage of stained cells 
with 26F8 MAb was 98.2%, 2.6% when preincubated with recombinant BST2, and 
98.1% when preincubated with Spartan protein (Figure 3.12). These results 




receptors expressed on the surface of MM1 and demonstrate the comparability of 
the generated antibody to the commercially available anti-BST2 26F8 MAb, in terms 
of specificity (Figure 3.13). 
Figure 3.11 LA5 MAb specificity.  
Flowcytometry staining of MM1 cell line, using the generated MAb LA5 and IgG1 
isotype control. The percentage of cell staining was reduced from 85.2% to 5.01% 
when LA5 MAb was preincubated with BST2 protein (5 ug/ml), while preincubation 
with Spartan protein did not lead to this reduction. In both columns, secondary 




Figure 3.12 26F8 MAb specificity.  
Flowcytometry staining of MM1 cell line using anti-BST2 (clone 26F8) MAb and IgG1 
isotype control. The percentage of cell staining was reduced from 98.2% to 2.6% 
when the 26F8 MAb was preincubated with BST2 protein, while preincubation with 
Spartan protein was not associated with a reduction. In both columns, secondary 




Figure 3.13 Specificity comparison of the LA5 and 26F8. 
Flowcytometry staining of MM1 cell line using of the generated anti-BST2-long 
(clone LA5) MAb and anti-BST2 (clone 26F8) MAb, preincubated with recombinant 
BST2 protein or irrelevant protein and using secondary antibody alone as a control. 











3.8 Flow Cytometry Staining of B Lineage and Breast Tissue Cell Lines 
        To analyze the expression of the long BST2 isoform in cancer and normal 
tissues, and to test our hypothesis that the long isoform is preferentially expressed in 
tumor tissues, the generated MAb (anti-BST2-long clone LA5) was used in FACS 
staining of two sets of cell lines, representing normal and malignant plasma cells and 
breast tissue. Observing differences in the cell staining percentages and intensity 
(mean fluorescence) between the normal and malignant cell lines might indicate a 
preferential expression of the long isoform of BST2 receptor. Using B lymphoblastoid 
cell lines (B-LCL) as a surrogate for normal B lymphocytes, no differences were 
observed in the cell staining percentage or mean fluorescence, when compared to 
MM1 and U266 multiple myeloma cell lines. Using LA5 MAb, the percentage of cell 
staining for B-LCL, MM1 and U266 were 99.3, 98.6, and 96.1%, respectively. This 
pattern of staining was also noticed with anti-BST2 26F8 MAb that recognizes both 
isoforms. No significant differences were observed and the percentage of cell 
staining for B-LCL, MM1 and U266 were 99.7, 99.6, and 97.1%, respectively (Figure 
3.14). While the FACS results clearly confirmed the expression of the long BST2 
isoform on the malignant B cells, it did not prove the preferential expression in 
malignant vs non-malignant B cell lineages. These results might suggest a non-
specific expression of the long isoform of BST2 in the spectrum of B cells. The mean 
fluorescence of cell staining with anti-BST2-long (clone LA5) or anti-BST2 (clone 
26F8) MAbs in B-LCL and U266 was similar, suggesting that the long isoform is not 




Figure 3.14 Flow cytometry staining of B cell lines.  
FACS staining of three cell lines, representing normal and malignant plasma cells, 
using the generated MAb against the long isoform of BST2 (LA5), and Anti-BST2 
(26F8), at a concentration of 1ug/ml. The secondary antibody alone was used as a 
control. 
A. B-LCL cell line. No statistically significant differences in staining were 
observed with the use of LA5 or 26F8 MAbs. The percentage of cell staining 
was 99.3% and 99.7%, respectively. Since 26F8 recognizes both isoforms, 
and LA5 only the long isoform, it could be assumed that only the long isoform 
is expressed.  
B. MM1 cell line. No statistically significant differences in staining were observed 




and 99.6%, respectively. The mean fluorescence was different, suggesting 
different molecule density on the cell surface. 
C. U266 cell line. No statistically significant differences in staining were observed 
with the use of LA5 or 26F8 MAbs. The percentage of cell staining was 96.1% 
and 97.1%, respectively, suggesting that only the long isoform is expressed. 
 
        In contrast to the B cell lines, FACS staining of breast tissue cell lines 
demonstrated different patterns with these two MAbs. At a concentration of 1 ug/ml, 
LA5 MAb showed minimal binding to MCF-10A, a non-malignant epithelial breast 
tissue cell line, as well as T47D, MDA-MB-231 and MCF7 human breast cancer cell 
lines. Percentages of cell staining were 2.4%, 2.6%, 1% and 0.43%, respectively 
(Figure 3.15). Using this same concentration, anti-BST2 clone 26F8 MAb resulted in 
a significantly higher staining of the MCF-10A cell line (staining percentage of 27.7% 
and p value < 0.05). Staining of the human breast cancer cell lines varied; upon 
comparison to the intensity of MCF-10A staining, insignificant differences were 
observed with MDA-MB-231 and MCF7 (percentage of staining was 28.4% and 
34.7%, respectively). However, a significant difference was noticed with the staining 
of the T47D human breast cancer cell line, with percentage of cell staining of 96.6% 
(Figure 3.15). With these results, neither MAbs revealed the differential expression 
of BST2 isoforms in the malignant versus nonmalignant cell lines, using flow 




Figure 3.15 Flow cytometry staining of breast tissue cell lines.  
FACS staining of four cell lines, representing normal and malignant breast tissue 
cells, using the MAb against the long isoform of BST2 (clone LA5) and the Anti-
BST2 (clone 26F8). Secondary antibody APC conjugated was used alone as a 
control. 
A. MCF-10A cell line: statistically significant differences (p value < 0.05) in 
staining were observed with the use of LA5 or 26F8 MAbs. The percentage of 
cell staining was 2.4% and 27.7%, respectively. 
B. MCF7 cell line: statistically significant differences (p value < 0.05) in staining 
were observed with the use of LA5 or 26F8 MAbs. The percentage of cell 




C. MDA-MB-231 cell line: statistically significant differences (p value < 0.05) in 
staining were observed with the use of LA5 or 26F8 MAbs. The percentage of 
cell staining was 1% and 28.4%, respectively. 
D. T47D cell line: statistically significant differences (p value < 0.05) in staining 
were observed with the use of LA5 or 26F8 MAbs. The percentage of cell 
staining was 2.6% and 96.6%, respectively. 
 
 
3.9 Immunohistochemistry Staining  
        To examine the diagnostic potential of the generated MAb and to determine the 
localization of the long isoform of BST2, immunohistochemistry technique was 
selected. The immunohistochemistry assays on the HEK-293 transduced cells 
demonstrated the ability of LA5 MAb to stain cells expressing the long isoform of 
BST2, but not the other isoforms. In contrast, the use of the 26F8 MAb was 
associated with the staining of cells expressing either isoform of BST2 (Figure 3.16). 
Moreover, these antibodies resulted in membranous to cytoplasmic staining, 











The staining patterns of transduced HEK-293 cell lines, using anti-BST2-long (clone 
LA5) and anti-BST2 (clone 26F8) MAbs, are as follow: 
A. Negative control (no staining). 
B. With LA5 MAb, cells expressing the long isoform of BST2 demonstrated 
grainy membranous to cytoplasmic staining, while no staining was observed 
in cell expressing the medium isoform. 
C. Positive control using anti-BST2 (clone 26F8) MAb. Membranous to 
cytoplasmic staining was observed in HEK293 cells expressing both the long 
and medium isoforms of BST2.  
         
        Through collaboration with Dr. Bravo’s laboratory at Hospital El Cruce (Buenos 
Aires, Argentina), immunohistochemistry staining was performed on patient-derived 
samples of breast cancer with these two antibodies. Using formalin fixed paraffin 
embedded (FFPE) tissue blocks of ductal breast carcinoma, the generated anti-
BST2-long MAb (LA5) was able to stain and identify infiltrating carcinoma cells, but 
not the normal surrounding acinar cells. In contrast, the anti-BST2 clone 26F8 MAb 
stained cells expressed BST2 but did not discriminate between the malignant cells 
and the surrounding normal acinar cells (Figure 3.17).  
.  
 










Figure 3.17 Immunohistochemistry slides of infiltrating ductal breast 
carcinoma surrounding normal acinus (Slides credit: Dr. Ines Bravo). 
Immunohistochemistry staining of breast cancer tissue revealing the expression of 







A. Infiltrating ductal breast carcinoma (yellow arrow) surrounding normal acinus 
(red arrows), using anti-BST2 clone 26F8 MAb. This antibody stained both 
the normal and malignant cells. 
B. Infiltrating ductal breast carcinoma (yellow arrow) surrounding normal acinus 
(white arrows), using anti-BST2-long clone LA5 MAb. This antibody stained 
the malignant cells only.  
 
        Within the breast ductal system, immunohistochemistry assays revealed the 
ability of the LA5 MAb to bind and stain specifically the malignant cells and to 
distinguish the surrounding normal ducts. On the other hand, the 26F8 MAb could 
not differentiate between the normal and malignant ducts, with a subsequent positive 
staining of cells in these two structures (Figure 3.18). This finding suggested that the 
specific epitope of LA5 that present in the long BST2 isoform might be exposed with 










Figure 3.18 Immunohistochemistry slides of infiltrating ductal breast 
carcinoma surrounding normal ducts (Slides credit: Dr. Ines Bravo). 
Immunohistochemistry staining of breast cancer tissue reveals the expression of the 








A. Infiltrating ductal breast carcinoma (yellow arrow) surrounding normal ducts 
(red arrow), using anti-BST2 clone 26F8 MAb. This antibody stained both the 
normal and malignant cells. 
B. Infiltrating ductal breast carcinoma (yellow arrow) surrounding normal ducts 
(white arrow), using anti-BST2-long clone LA5 MAb. This antibody stained the 
malignant cells only.  
 
3.10 BST2 Silencing Via shRNA 
        To explore BST2 roles in breast tissue carcinogenesis, a loss of function 
approach with BST2-targeting short hairpin RNA (shRNA) was used. To examine the 
efficiency of this approach, flowcytometry staining of cell lines was performed. By 
analyzing the percentage of cell staining among the non-transduced T47D cell line 
(T47D-WT), T47D cell line with a non-silenced transduction (T47D-NS), and T47D 
cell line with BST2-silenced transduction (T47D BST2-silenced), I was able to 
confirm a subpopulation of cells that were GFP-positive and APC-negative. The 
green fluorescent protein (GFP) indicates efficient lentiviral transduction, while APC-
conjugated secondary antibodies that interact with anti-BST2 primary antibodies 
suggests the presence of BST2 membrane receptors (Figure 3.19). Consequently, 
the GFP-positive APC-negative cells were considered BST2-silenced cells. Those 
cells were collected via cell sorting, expanded, and studied in comparison to T47D-













A and B: Dot plot figures of T47D-WT staining, using APC-conjugated secondary 
antibodies alone as a control (Figure A) and anti-BST2 clone 26F8 in a 
concentration of 2 ug/ml and secondary antibodies conjugated with APC (Figure B).  
C and D: Dot plot figures of T47D-NS staining, using APC-conjugated secondary 
antibodies alone as a control (Figure C) and anti-BST2 clone 26F8 in a 
concentration of 2ug/ml and secondary antibodies conjugated with APC (Figure D). 
Figure C shows a population of cells (64.2%) that is GFP-positive, while figure D 
demonstrates a percentage of GFP +ve, APC +ve cells = 57.1%. These GFP +ve, 
BST2 +ve cells were collected via cell sorting, and considered a T47D cell line with a 
nonsilenced transduction (T47D-NS). 
E and F:  Dot plot figures of T47D BST2-silenced staining, using APC-conjugated 
secondary antibodies alone as a control (Figure E) and anti-BST2 clone 26F8 in a 
concentration of 2ug/ml and secondary antibodies conjugated with APC (Figure F). 
Figure E shows a population of cells (58.7 %) that is GFP-positive, while Figure F 
demonstrates a percentage of GFP +ve, APC -ve cells = 48.9%. These GFP +ve, 
BST2 -ve cells were collected via cell sorting, and considered a T47D cell line with a 








3.11 Cell Viability Assay 
        To examine the impact of BST2 silencing on the viability of T47D, CellTiter-Glo 
viability assay was performed. A statistically significant reduction in viability was 
observed with BST2 silencing (p value = 0.033), compared to the viability observed 
in T47D-WT and T47D-non silenced controls. Figure 3.20 demonstrates the mean 















































Figure 3.20 Cell Viability assay. This figure shows the statistically significant 
reduction in the viability of the T47D cell line with silenced BST2 (P < 0.05), 





3.12 Cell Proliferation Assay 
        To examine the impact of BST2 silencing on the proliferation of T47D, XTT cell 
proliferation assay was performed. No statistically significant change was observed 
with BST2 silencing (p value = 0.6), compared to the proliferation observed in T47D-
WT and T47D-non silenced controls. Figure 3.21 demonstrates the mean and 95% 













































Figure 3.21 Cell Proliferation assay. This figure shows no statistically significant 
change in the proliferation of the T47D cell line with silenced BST2 (p value = 0.6), 





3.13 Protein Expression in T47D Cell Lines Pre- and Post BST2 Silencing 
        To define the adaptive cellular responses to the silencing of BST2 gene and 
understand a possible pathway to reduced viability post-BST2 silencing, cellular 
protein expression was explored. The data received from the Reverse Phase Protein 
Array (RPPA) assessed the relative protein expression of 466 genes in a non-
transduced T47D cell line (T47D-WT), T47D cell line with a nonsilenced transduction 
(T47D-NS), and T47D cell line with BST2 silenced transduction (T47D BST2-
silenced). After data cleaning and value analysis, the relative protein expression of 
99 genes showed changes after BST2 silencing. The log2 values of the normalized 
linear data were median-centered and used to generate a heatmap to visualize the 
changes in the relative protein expression observed after BST2 silencing, compared 




















Figure 3.22 Heatmap of T47D cell lines.  
This heatmap visualizes the changes in the protein expression of 99 genes 
associated with the silencing of the BST2 gene in T47D cell lines. The red color 
















































































































suggests an increase above the median value, while the green color suggests a 
decrease below the median value. 
 
        By analyzing the normalized linear values associated with each protein, 
statistically significant upregulation (p value < 0.05) was found in the following genes 
with the silencing of BST2: MAPK1/MAPK3, HES1, FN1 and STAT3 (Figure 3.23).  
Figure 3.23 T47D upregulated genes after BST2 silencing.  
This figure compares the level of protein expression of 10 genes among the T47D-
WT (red), T47D-NS (orange), and T47D BST2-silenced (Blue) cell lines. There was 
a statistically significant upregulation of the following genes with the silencing of 
BST2: MAPK1/MAPK3, HES1, FN1 and STAT3 (p value < 0.05). 
.. .. .. .. 




        In contrast, no statistically significant downregulation of genes was observed 

































































Figure 3.24 T47D downregulated genes after BST2 Silencing.  
This figure compares the level of protein expression of 10 genes among the T47D-
WT (red), T47D-NS (orange) and T47D-BST2 silenced (blue) cell lines. There was 










4. Discussion & Future Directions 
4.1 Discussion 
        Since the introduction of the hybridoma technique by Nobel prize winners 
Georges Kohler and Cesar Milstein in 1975, the production and utilization of 
monoclonal antibodies have faced several challenges, mostly related to their 
immunogenicity, efficacy, and toxicity (36, 37). As of 2018, a list of 29 MAbs have 
been approved by the Food and Drug Administration for the treatment of various 
cancers (37) and the list is expected to grow as more cellular targets are being 
discovered. These cellular targets could be unique to malignant cells or simply 
overexpressed in cancers (38). However, the uniqueness or overexpression of a 
cellular target cannot predict the usefulness of a generated MAb. The distribution 
and density of a cellular target, as well as the possibility of variation in the target 
affinity, should be analyzed in both the tumor and the cross-reacting normal tissues. 
The excessive reactivity of MAbs with normal tissues may significantly reduce the 
biodistribution of the therapeutic agent and negatively impact intratumoral 
distribution. Moreover, this excessive reactivity may increase the potential to induce 
severe toxic effects (39). In 2001, a phase I clinical study was conducted to examine 
the efficacy of anti-BST2 MAb in the treatment of multiple myeloma patients. The 
poor response rate was attributed to “probably diminished activity of effector cells in 
this heavily pretreated patient population” (25); however, the widespread distribution 
of BST2 in tissues and organs was not recognized at that time, which may have 
contributed to the trial outcome. Understanding the role(s) of a particular cellular 




therapeutic MAb (40). The role of BST2 in carcinogenesis of various organs has not 
yet been fully elucidated. Furthermore, the discovery of different isoforms with 
distinct signaling activities, via the NF-kappa B pathway (28), have led us to study 
this cellular target.  Based on the hypothesis, we believed that further analysis of the 
expression of BST2 isoforms in various cells and tissues could provide a better 
understanding of their role(s) in carcinogenesis, thereby offering an opportunity to 
recognize BST2 isoforms as potential targets for diagnostic and/or therapeutic 
MAbs. 
        In my study, I successfully generated a MAb that targets the long isoform of 
BST2, as described by its Japanese inventors, Jun Ohkawa and Yumiko Kakogawa 
(patent no. JP2004173767, 2005). Prior to the selection and production of the anti-
BST2-long MAb, 563 clones went through extensive screening experiments that 
consecutively narrowed down the list of the potential candidates to a single clone, 
namely LA5. Although the final list had three clones (LA1, LA5 and BM7), the 
selection of LA5 was based on a combination of MAb specificity and binding affinity 
to the long isoform of BST2 expressed by the HEK293-long transfectant and not the 
transfectant expressing the medium isoform of BST2, i.e. HEK293-medium.  Using 
anti-BST2-long MAb (clone LA5), FACS staining of HEK293 transfectants 
demonstrated slight insignificant binding to the medium isoform. This might be 
attributed to the fact that the sequence of the peptide used for mice immunization 
minimally overlapped with the amino acid sequence of the medium isoform. Upon 
designing the peptide for immunization, targeting the extracellular domain of the long 




immunogenicity) were taken into consideration. While not part of the main antigenic 
determinant of the peptide (RENQVLSVRI), the first five amino acids of the synthetic 
peptide (at the amino terminal) could be responsible for the minimal reactivity of the 
MAb with the medium isoform of BST2. Regardless, LA5 MAb demonstrated 
superiority in selectively binding to the long isoform of BST2, when compared to anti-
BST2 clone 26F8 MAb, an antibody previously developed by our laboratory that 
recognizes all isoforms. LA5 offered an excellent method to examine my hypothesis 
of preferential expression of BST2 isoforms.  
        In terms of their affinity to the BST2 protein, the kinetic assays performed on 
the LA5 and 26F8 MAbs showed comparable results. LA5 MAb had a nanomolar 
value for the equilibrium dissociation constant (KD), indicating a high affinity to BST2 
molecules. This feature may allow the use of LA5 MAbs as a valuable diagnostic tool 
to detect the expression of the long isoform of BST2 in various in-vitro assays and 
immunohistochemistry staining. While it is an important criterion for a good antibody, 
this nanomolar value of affinity may also limit the therapeutic potential of LA5 MAbs, 
especially for solid tumors. Adams et al. found that tumor retention of monoclonal 
antibodies plateaued at higher affinities (more than 1*E-9 M) and were associated 
with lower tumor: blood ratios (41). The combination of this level of affinity and high 
interstitial pressure, a common feature in many solid tumors, may create the “binding 
site barrier effect” that can significantly impede the transport of MAbs from the blood 
vessels deep into the tumor. With a higher affinity to a specific target on cancer cells, 
MAbs may competently bind to the perivascular cancer cells, but intratumor 




distribution of the MAb within the tumor mass (41, 42). Measuring the affinity of LA5 
MAb interaction with BST2 receptors expressed on cells, instead of BST2 protein, 
could provide more insight into the kinetics of this interaction. Results from the 
specificity assays strongly indicated the high specificity of clone LA5 MAb to bind to 
its target, the long isoform of BST2. 
        After characterizing the generated MAb, I examined my hypothesis of the 
preferential expression of the long isoform of BST2 on cancerous cells via flow 
cytometry assays on various cell lines and immunohistochemistry staining of patient-
derived samples of breast cancer. By comparing the flow cytometry staining of B cell 
lines using LA5 and 26F8 MAbs, we were able to confirm long isoform expression in 
the B cell lineage, as the percentages of stained cells were identical. However, the 
results did not reveal a differential staining between the transformed B-LCL (used as 
a surrogate for normal B cells) and malignant B cell lines. Several possibilities could 
explain the FACS data; as discussed previously, the generated anti-BST2-long LA5 
MAb has minimal cross-reactivity with the HEK293 medium isoform cells (0.3% 
stained cells) and the generation of an antibody specific for the medium isoform 
could clarify this issue. Moreover, B-LCL, a non-malignant B cell line that has been 
transformed by the in-vitro infection of resting B cells with Epstein-Barr virus, was 
used as a surrogate for normal B cells. While this cell line could be a reliable source 
for “normal” B cells for testing carcinogen sensitivity and DNA repair (43), it might 
not be suitable to examine the expression of BST2 isoforms in “normal” tissues. 
Repeating the assay with human peripheral blood B cells would be recommended. 




to different fluorochromes and confocal microscopy analysis to examine isoforms 
colocalization could help in the elucidation of this observation. On the other hand, 
both non-malignant (MCF-10A) and malignant (MDA-MB-231, T47D and MCF7) 
breast epithelial cell lines stained poorly with LA5 MAb in the FACS assay. This poor 
staining could be secondary to technical aspects. As adherent cell lines, the breast 
tissue cell lines were detached with trypsin. Trypsinization might be associated with 
the destruction of the BST2 epitope recognized by LA5; alternative detachment 
solutions should thus be attempted. A low concentration of LA5 might also be 
inadequate for efficient staining; a serial higher concentration might reveal an 
increase in the mean fluorescence or staining percentage in FACS and would be 
suggested. Regardless, the clone LA5 demonstrated superiority over anti-BST2 
clone 26F8 in the immunohistochemistry staining of breast ductal adenocarcinoma. 
The 26F8 MAb was associated with staining of both normal and malignant cells 
expressing BST2 in the analyzed tumor tissue sections.  In contrast, the LA5 MAb 
demonstrated the capability to recognize and stain malignant ductal cells while 
excluding normal cells. This differentiation pattern in staining was observed while 
malignant ductal cells infiltrated normal acinar tissues or were surrounded by normal 
ductal tissues. While this observation strongly suggests the ability of the LA5 MAb to 
successfully identify malignant infiltration in breast cancers in immunohistochemistry 
assay at certain conditions and concentrations, it cannot be interpreted as solid 
proof of the preferential expression of the long isoform of BST2 in breast tissue 
malignancies. Moreover, it is well known that formalin-fixed paraffin embedded 




instance, in native conditions such as in FACS assays. Cai et al. reported an 
upregulation of BST2 expression in breast cancer (20) and Mahauad-Fernandez et 
al. attributed this overexpression to a hypomethylation at the BST2 gene level (21). 
This BST2 overexpression might be a factor that enabled the LA5 MAb to detect 
only malignant cells, while missing normal cells. Additionally, it is not uncommon that 
certain antibodies are suitable for tissue staining and not for FACS, due to a different 
exposure of the epitope under tissue manipulations. Regardless, clone LA5 could be 
considered a valuable addition in breast cancer diagnostics. The ability of LA5 MAbs 
to detect cancer cells embedded in normal tissues within patient samples might 
increase the sensitivity and specificity during pathology examination. Moreover, this 
MAb might be helpful in confirming negative or clear margins, following surgical 
removal of malignancy. This anti-BST2-long (clone LA5) MAb It might also be 
examined on specimens of other cancers, e.g. head and neck, liver, ovarian and 
colorectal cancers, as these malignancies are associated with the overexpression of 
BST2. 
        To further explore the roles of BST2 in breast tissue malignancies, a loss-of-
function approach with BST2-targeting short hairpin RNA (shRNA) was used. BST2 
Silencing was associated with a statistically significant reduction in the viability of the 
T47D cell line, and no variation in proliferative ability was observed. While Cai et al. 
used a gain-of-function approach to study BST2 in breast cancer, they noticed an 
increase in the S-phase cell population (an indicator of proliferation) with the 
introduction of BST2 to the MDA-MB-231 breast cancer cell line (20). In another 




231 cell line and circulating tumor cells with the suppression of BST2, as it rendered 
the cells susceptible to anoikis (21). 
        Variations in gene expression as a consequence of BST2 silencing were 
studied in the T47D cell line, with the view to assess the adaptive cellular response. 
Among the 466 genes analyzed via RPPA, only four genes demonstrated 
statistically significant changes. Notably, STAT3 demonstrated a significant 
upregulation following BST2 silencing in our assays. The signal transducer and 
activator of transcription 3 (STAT3) has many physiological roles in relation to 
several cytokines and growth factors, but it also has carcinogenic roles, especially in 
tumor initiation and progression. In their study of STAT3 in breast cancer, Segatto et 
al. observed STAT3 signaling in breast cancer cells in response to treatment. This 
STAT3 activation mediates survival and dormancy states, supporting the formation 
of locally recurrent and/or distant metastatic disease (44). This finding could point to 
the therapeutic use of anti-BST2 MAbs causing recurrence in breast cancer. While 
STAT3 overexpression with BST2 silencing might be nonspecific, it clearly indicates 
the significant role of BST2 in breast tumorigenesis. Other significantly 
overexpressed genes after BST2 silencing were MAPK1/MAPK3 and HES1. Si et al. 
found that overexpression of MAPK1 in breast cancer cells was associated with 
enhanced proliferation and chemotherapeutic resistance (45). Hairy and enhancer of 
split homolog-1 (HES1), a transcriptional repressor, has multiple physiological roles 
in cellular differentiation, apoptosis, and cell cycle arrest; overexpression of this 
gene was found in different malignancies, including lung, ovarian and colorectal 




cancer cell line with the induced expression of HES1 (46). These findings might 
explain why no changes in the proliferation of T47D cells were observed with BST2 
silencing. Lastly, FN1, a glycoprotein involved in cellular adhesion and migration, 
was significantly overexpressed after BST2 silencing. A study conducted by Yang et 
al. reported enhanced invasion and migration capabilities of the MCF7 cell line with 
the upregulation of FN1, as well as an increased resistance to chemotherapy 
(doxorubicin) (47). Therefore, FN1 upregulation may suggest more aggressive 
behavior in the T47D cell line in response to BST2 silencing. To summarize, the 
upregulation of these genes demonstrated the adaptive response that breast cancer 
cells might reveal with targeting BST2. It is also an example of the different survival 
mechanisms that the tumor cells may use should a critical pathway become 
compromised.  
        Finally, the minimal reactivity of the generated MAb to the HEK293 transfectant 
expressing the medium isoform could be considered a limitation of the generated 
MAb. Designing a new peptide immunogen that is shorter and modified with 
fluorocarbon to enhance immunogenicity could be helpful in generating MAbs with 
no binding to the medium isoform.  
        To conclude, a new MAb called LA5 was generated against the long isoform of 
BST2, a molecule highly expressed in several tumor types. Staining of malignant B 
cell lines using the new antibody confirmed the specific expression of the long 
isoform of BST2 in malignant B cell lines, although further experiments are required 
to analyze if the expression is restricted to cancer cells or not. Moreover, the LA5 




infiltration of malignant breast ductal carcinoma in patient samples. Lastly, this study 
provided insight about variations in gene expression in breast cancer cells with 
BST2 silencing. While these changes might potentially enhance the survival and 



















4.2 Future Directions 
        Identifying a cancer-specific cellular target is a critical factor that can assist in 
creating a successful path for target therapies. Given its widespread distribution and 
the vital roles it plays in the carcinogenesis of multiple tissues and organs, more 
advanced studies on the isoforms of BST2 should be conducted. In particular, 
describing the distribution of BST2 isoforms in the various organs and tissues, as 
well as the factors and conditions responsible for the expression and predominance 
of a single isoform over another, could lead to a better understanding of this protein 
and define the reliability of using BST2 for potential target therapy. Since these 
isoforms are based on posttranscriptional modifications, approaching these research 
questions through bioinformatics and RNA-Seq data could be helpful.  
        Using the monoclonal antibody approach, expression of the long BST2 isoform 
in other cell lines and patient samples should be explored. Several tumors reveal an 
elevated expression of BST2, and representative cell lines could be examined 
through flow cytometry assays with anti-BST2-long (clone LA5) MAbs. Employing 
immunohistochemistry to test the potential diagnostic value of the generated MAb on 
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